J H S You1, F W H Chan, R S M Wong, G Cheng. 1. School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. joyceyou@cuhk.edu.hk
Abstract
AIM: To examine the optimal range of International Normalized Ratio (INR) for Chinese patients receiving warfarin for moderate-intensity anticoagulation. METHODS: This was a retrospective cohort study conducted at the ambulatory setting of a 1400-bed public teaching hospital in Hong Kong. The INR measurements and occurrence of serious or life-threatening haemorrhagic and thromboembolic events among patients newly started on warfarin from 1 January 1999 to 30 June 2001 for indications with target INR 2-3 were analysed. The INR-specific incidence of bleeding and thromboembolism were calculated. RESULTS: A total of 491 patients were included, contributing to 453 patient-years of observation period. Forty-seven of the 491 patients experienced 25 haemorrhagic events (5.5 per 100 patient-years) and 27 thromboembolic events (6.0 per 100 patient-years). The percentage of patient-time spent within therapeutic INR range (2-3), INR <2 and INR >3 were 50, 44 and 6%, respectively. The incidence of either haemorrhagic or thromboembolic events was lowest (< or =4 events per 100 patient-years) at INR values between 1.8 and 2.4. CONCLUSIONS: An INR of 1.8-2.4 appeared to be associated with the lowest incidence rate of major bleeding or thromboembolic events in a cohort of Hong Kong Chinese patients receiving warfarin therapy for moderate-intensity anticoagulation.
AIM: To examine the optimal range of International Normalized Ratio (INR) for Chinese patients receiving warfarin for moderate-intensity anticoagulation. METHODS: This was a retrospective cohort study conducted at the ambulatory setting of a 1400-bed public teaching hospital in Hong Kong. The INR measurements and occurrence of serious or life-threatening haemorrhagic and thromboembolic events among patients newly started on warfarin from 1 January 1999 to 30 June 2001 for indications with target INR 2-3 were analysed. The INR-specific incidence of bleeding and thromboembolism were calculated. RESULTS: A total of 491 patients were included, contributing to 453 patient-years of observation period. Forty-seven of the 491 patients experienced 25 haemorrhagic events (5.5 per 100 patient-years) and 27 thromboembolic events (6.0 per 100 patient-years). The percentage of patient-time spent within therapeutic INR range (2-3), INR <2 and INR >3 were 50, 44 and 6%, respectively. The incidence of either haemorrhagic or thromboembolic events was lowest (< or =4 events per 100 patient-years) at INR values between 1.8 and 2.4. CONCLUSIONS: An INR of 1.8-2.4 appeared to be associated with the lowest incidence rate of major bleeding or thromboembolic events in a cohort of Hong Kong Chinese patients receiving warfarin therapy for moderate-intensity anticoagulation.
Authors: R Hull; J Hirsh; R Jay; C Carter; C England; M Gent; A G Turpie; D McLoughlin; P Dodd; M Thomas; G Raskob; P Ockelford Journal: N Engl J Med Date: 1982-12-30 Impact factor: 91.245
Authors: R Altman; J Rouvier; E Gurfinkel; O D'Ortencio; R Manzanel; L de La Fuente; R G Favaloro Journal: J Thorac Cardiovasc Surg Date: 1991-03 Impact factor: 5.209
Authors: Fredric W H Chan; Raymond S M Wong; Wing-Hung Lau; Thomas Y K Chan; Gregory Cheng; Joyce H S You Journal: Br J Clin Pharmacol Date: 2006-11 Impact factor: 4.335
Authors: Joyce H S You; Raymond S M Wong; Mary M Y Waye; Yawei Mu; Cadmon K Lim; Kai-Chow Choi; Gregory Cheng Journal: J Thromb Thrombolysis Date: 2011-01 Impact factor: 2.300
Authors: Natalie Oake; Alison Jennings; Alan J Forster; Dean Fergusson; Steve Doucette; Carl van Walraven Journal: CMAJ Date: 2008-07-29 Impact factor: 8.262
Authors: Frances Edwards; Paul Arkell; Lesley M Roberts; David Gendy; Christina Siew-Hie Wong; Joanna Chee Yien Ngu; Lee Len Tiong; Faridha Mohd Salleh Bibi; Lana Yin Hui Lai; Tiong Kiam Ong; Michael Abouyannis Journal: J Thromb Thrombolysis Date: 2014 Impact factor: 2.300